Here are five things to know about the systems sold:
1. After the fourth quarter, the company has 83 Renaissance systems globally and 46 in the United States. This is up over 63 systems sold globally and 34 in the United States in 2013.
2. Mazor expects to report $5.7 million in fourth quarter revenue when the final financial report is released.
3. Full-year revenue is anticipated at $21 million, slightly higher than the $20 million reported in 2013.
4. Even though the company was in negotiations to complete sales of at least one Renaissance system with several hospitals in the Untied States when the quarter closed, the agreements weren’t finalized and that will impact the fourth quarter revenue.
5. Mazor will continue to pursue these agreements in 2015.
“We are still at the very early stage of developing the robotic spine surgery market and continue to experience a high level of interest and sales activity in the Renaissance system in our key markets,” said Mazor CEO Ori Hadomi. “We remain confident that with strong data supporting the clinical and economic benefit of the Renaissance system and continued sales and marketing efforts we will expand our presence in these markets over the longer term.”
More articles on orthopedic devices:
Zimmer, Biomet, Zyga Technology & more—5 key notes
MiMedx files suit against Organogenesis—7 things to know
Is the Zimmer-Biomet acquisition unraveling? 5 quick updates
